Takeda selects global CSR programs for developing and emerging countries

3 July 2017

Takeda Pharmaceutical (TYO: 4502) has selected three global CSR (corporate social responsibility) programs that emphasize prevention for health in developing and emerging countries.

These programs were selected based on the results of an online vote of all Takeda employees worldwide. Employees from more than 70 countries cast their votes, and selected three programs run by organizations with proven track records: UNICEF, Plan International, and JOICFP. All three of these programs are large-scale programs that are being launched by the aforementioned organizations in partnership with Takeda, Japan’s largest pharma company.

Takeda will commit a total of 2.75 billion yen ($24.5 million) to these three programs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK